Revance announces publication of SAKURA 1, SAKURA 2 results
Revance Therapeutics announced the publication of results from the Phase 3 studies, SAKURA 1 and SAKURA 2, in Plastic and Reconstructive Surgery, or PRS, the peer reviewed Journal of the American Society of Plastic Surgeons. These two Phase 3 studies evaluated Revance's long-acting neuromodulator product, DaxibotulinumtoxinA for Injection, or DAXI, for the treatment of moderate and severe glabellar lines. This manuscript presents the findings from SAKURA 1 and 2 side-by-side, which demonstrate the consistency of efficacy and safety results evident between the two pivotal studies, as well as the reproducibility of these outcomes with DAXI across patients and clinical trial sites. Both SAKURA 1 and SAKURA 2 demonstrated that half of the patients treated maintained none or only mild frown lines for at least 24 weeks, after a single treatment. Additionally, frown lines did not return to their pre-treatment severity for at least 26-28 weeks for half of the patients treated. "The publication in PRS highlights the quality of the Phase 3 clinical data and underscores how DAXI unlocks the true potential for a next generation neuromodulator product," said Mark Foley, President and CEO of Revance Therapeutics.